Terms: = Lung cancer AND SOCS1, O15524, 8651, ENSG00000185338, SOCS-1, SSI-1, SSI1, Cish1, JAB, CISH1, CIS1, TIP3 AND Treatment
18 results:
1. Long non-coding RNA MIR22HG inhibits the proliferation and migration, and promotes apoptosis by targeting microRNA-9-3p/ socs1 axis in small cell lung cancer cells.
Wang S; Wang Y; Li S; Nian S; Xu W; Liang F
Mol Biol Rep; 2023 Sep; 50(9):7445-7456. PubMed ID: 37479878
[TBL] [Abstract] [Full Text] [Related]
2. Ubenimex Combined with Pemetrexed Upregulates socs1 to Inhibit lung Adenocarcinoma Progression via the JAK2-STAT3 Signaling Pathway.
Chen Q; Wu B; Ge P; Zhang P; Chen X
Dis Markers; 2022; 2022():5614939. PubMed ID: 35789603
[TBL] [Abstract] [Full Text] [Related]
3. Synergistic activation of p53 by actinomycin D and nutlin-3a is associated with the upregulation of crucial regulators and effectors of innate immunity.
Krześniak M; Zajkowicz A; Gdowicz-Kłosok A; Głowala-Kosińska M; Łasut-Szyszka B; Rusin M
Cell Signal; 2020 May; 69():109552. PubMed ID: 32032660
[TBL] [Abstract] [Full Text] [Related]
4.
Saigi M; Alburquerque-Bejar JJ; Mc Leer-Florin A; Pereira C; Pros E; Romero OA; Baixeras N; Esteve-Codina A; Nadal E; Brambilla E; Sanchez-Cespedes M
Clin Cancer Res; 2018 Sep; 24(18):4579-4587. PubMed ID: 29898990
[No Abstract] [Full Text] [Related]
5. Phase I clinical trial of a novel autologous modified-DC vaccine in patients with resected NSCLC.
Ge C; Li R; Song H; Geng T; Yang J; Tan Q; Song L; Wang Y; Xue Y; Li Z; Dong S; Zhang Z; Zhang N; Guo J; Hua L; Chen S; Song X
BMC Cancer; 2017 Dec; 17(1):884. PubMed ID: 29268708
[TBL] [Abstract] [Full Text] [Related]
6. MiR-21 and MiR-155 promote non-small cell lung cancer progression by downregulating socs1, SOCS6, and PTEN.
Xue X; Liu Y; Wang Y; Meng M; Wang K; Zang X; Zhao S; Sun X; Cui L; Pan L; Liu S
Oncotarget; 2016 Dec; 7(51):84508-84519. PubMed ID: 27811366
[TBL] [Abstract] [Full Text] [Related]
7. Signal transducer and activator of transcription 1 (STAT1) acts like an oncogene in malignant pleural mesothelioma.
Arzt L; Kothmaier H; Halbwedl I; Quehenberger F; Popper HH
Virchows Arch; 2014 Jul; 465(1):79-88. PubMed ID: 24838635
[TBL] [Abstract] [Full Text] [Related]
8. Molecular mechanism underlying the antiproliferative effect of suppressor of cytokine signaling-1 in non-small-cell lung cancer cells.
Shimada K; Serada S; Fujimoto M; Nomura S; Nakatsuka R; Harada E; Iwahori K; Tachibana I; Takahashi T; Kumanogoh A; Kishimoto T; Naka T
Cancer Sci; 2013 Nov; 104(11):1483-91. PubMed ID: 23962256
[TBL] [Abstract] [Full Text] [Related]
9. Nuclear EGFR as a molecular target in cancer.
Brand TM; Iida M; Luthar N; Starr MM; Huppert EJ; Wheeler DL
Radiother Oncol; 2013 Sep; 108(3):370-7. PubMed ID: 23830194
[TBL] [Abstract] [Full Text] [Related]
10. Mutant p53 attenuates the anti-tumorigenic activity of fibroblasts-secreted interferon beta.
Madar S; Harel E; Goldstein I; Stein Y; Kogan-Sakin I; Kamer I; Solomon H; Dekel E; Tal P; Goldfinger N; Friedlander G; Rotter V
PLoS One; 2013; 8(4):e61353. PubMed ID: 23630584
[TBL] [Abstract] [Full Text] [Related]
11. Regulation of the MIR155 host gene in physiological and pathological processes.
Elton TS; Selemon H; Elton SM; Parinandi NL
Gene; 2013 Dec; 532(1):1-12. PubMed ID: 23246696
[TBL] [Abstract] [Full Text] [Related]
12. Economic implications of using pegfilgrastim rather than conventional G-CSF to prevent neutropenia during small-cell lung cancer chemotherapy.
Tan Sean P; Chouaid C; Hettler D; Baud M; Hejblum G; Tilleul P
Curr Med Res Opin; 2009 Jun; 25(6):1455-60. PubMed ID: 19419340
[TBL] [Abstract] [Full Text] [Related]
13. Impaired downregulation following erythropoietin receptor activation in non-small cell lung carcinoma.
Dunlop EA; Maxwell AP; Lappin TR
Stem Cells; 2007 Feb; 25(2):380-4. PubMed ID: 17038666
[TBL] [Abstract] [Full Text] [Related]
14. SOCS-3 is frequently methylated in head and neck squamous cell carcinoma and its precursor lesions and causes growth inhibition.
Weber A; Hengge UR; Bardenheuer W; Tischoff I; Sommerer F; Markwarth A; Dietz A; Wittekind C; Tannapfel A
Oncogene; 2005 Oct; 24(44):6699-708. PubMed ID: 16007169
[TBL] [Abstract] [Full Text] [Related]
15. Activity of the suppressor of cytokine signaling-3 promoter in human non-small-cell lung cancer.
He B; You L; Xu Z; Mazieres J; Lee AY; Jablons DM
Clin Lung Cancer; 2004 May; 5(6):366-70. PubMed ID: 15217536
[TBL] [Abstract] [Full Text] [Related]
16. SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer.
He B; You L; Uematsu K; Zang K; Xu Z; Lee AY; Costello JF; McCormick F; Jablons DM
Proc Natl Acad Sci U S A; 2003 Nov; 100(24):14133-8. PubMed ID: 14617776
[TBL] [Abstract] [Full Text] [Related]
17. Cost-minimisation analysis of three regimens of chemotherapy (docetaxel-cisplatin, paclitaxel-cisplatin, paclitaxel-carboplatin) for advanced non-small-cell lung cancer.
Rubio-Terrés C; Tisaire JL; Kobina S; Moyano A
Lung Cancer; 2002 Jan; 35(1):81-9. PubMed ID: 11750717
[TBL] [Abstract] [Full Text] [Related]
18. p53-independent apoptosis mediated by tachpyridine, an anti-cancer iron chelator.
Abeysinghe RD; Greene BT; Haynes R; Willingham MC; Turner J; Planalp RP; Brechbiel MW; Torti FM; Torti SV
Carcinogenesis; 2001 Oct; 22(10):1607-14. PubMed ID: 11576999
[TBL] [Abstract] [Full Text] [Related]
